Abstract:
Disease recurrence perception plays a key role in disease management and subsequent disease recurrence prevention. However, there are no specific tools for assessing disease recurrence perception in patients with inflammatory bowel disease (IBD) characterized by alternating remission and recurrence. To develop and validate an instrument for measuring disease recurrence perception of patients with IBD, the study was conducted in two steps: (1) instrument development and (2) psychometric tests. A total of 623 patients with IBD participated in the study. The common sense model of illness self-regulation (CSM) was used as a framework for instrument development. The administered version contained 48 items intended to be relevant to at least one of the six dimensions of the model. Based on preliminary analyzes, 12 items were deleted leaving 36 items for more detailed psychometric and factor analyzes. The Cronbach\'s alpha coefficient of the total 36-item instrument was 0.915. The content validity indexes at item and scale levels were satisfactory. The test-retest reliability of the total instrument was 0.870. Exploratory principal components analysis (n = 278) was used to identify six components congruent with intended CSM constructs that accounted for 62.6% of total item variance. Confirmatory factor analysis (n = 345) found acceptable fit for the six factor measurement model (χ2/df = 1.999, GFI = 0.846, NFI = 0.855, IFI = 0.922, TLI = 0.910, CFI = 0.921, RMSEA = 0.054). Overall, the DRPSIBD demonstrated satisfactory reliability and validity to warrant further development as a measure of disease recurrence perception of patients with IBD.
摘要:
疾病复发感知在疾病管理和随后的疾病复发预防中起着关键作用。然而,对于以交替缓解和复发为特征的炎症性肠病(IBD)患者,目前尚无特异性评估疾病复发感知的工具.为了开发和验证一种测量IBD患者疾病复发感知的仪器,该研究分为两个步骤:(1)仪器开发和(2)心理测验。共有623名IBD患者参与了这项研究。疾病自我调节(CSM)的常识模型被用作仪器开发的框架。所管理的版本包含48个旨在与模型的六个维度中的至少一个相关的项目。根据初步分析,删除了12个项目,留下36个项目进行更详细的心理测量和因素分析。总共36项仪器的Cronbachα系数为0.915。项目和量表级别的内容效度指标令人满意。整个仪器的测试-重测可靠性为0.870。使用探索性主成分分析(n=278)来鉴定与预期CSM构建体一致的六个成分,占总项目方差的62.6%。验证性因素分析(n=345)发现六因素测量模型的拟合可接受(χ2/df=1.999,GFI=0.846,NFI=0.855,FI=0.922,TLI=0.910,CFI=0.921,RMSEA=0.054)。总的来说,DRPSIBD显示出令人满意的信度和效度,值得进一步开发作为IBD患者疾病复发感知指标.